WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 18, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, November 2, 2018 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 27, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 31, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Canaccord Genuity Growth Conference .
Mirvetuximab Soravtansine Granted Fast Track Designation by FDA Encouraging Combination Data Reported from FORWARD II Expansion Cohort of Mirvetuximab with Avastin ® ; Initial Data from Expansion Cohort in Combination with Keytruda ® to be Presented at ESMO $163 Million Net Proceeds from Public
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 12, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 21, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 18, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for its lead
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common